1.上海中医药大学肝病研究所,肝肾疾病病证教育部重点实验室(上海 201203)
2.上海中医药大学附属曙光医院肿瘤科(上海 201203)
3.上海中医药大学附属曙光医院肿瘤研究所(上海 201203)
张志鹏,男,博士研究生,主要从事中药防治消化系统疾病和肿瘤的研究工作
刘宁宁,副主任医师;E-mail:liuningning689@126.com
扫 描 看 全 文
张志鹏,冯媛媛,王炎,等.结直肠癌根治术后复发转移相关因素的回顾性研究[J].上海中医药杂志,2023,57(9):27-32.
ZHANG Zhipeng,FENG Yuanyuan,WANG Yan,et al.Retrospective study on factors related to recurrence and metastasis after radical resection of colorectal cancer[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(9):27-32.
张志鹏,冯媛媛,王炎,等.结直肠癌根治术后复发转移相关因素的回顾性研究[J].上海中医药杂志,2023,57(9):27-32. DOI: 10.16305/j.1007-1334.2023.2302085.
ZHANG Zhipeng,FENG Yuanyuan,WANG Yan,et al.Retrospective study on factors related to recurrence and metastasis after radical resection of colorectal cancer[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(9):27-32. DOI: 10.16305/j.1007-1334.2023.2302085.
目的,2,探讨结直肠癌根治术后复发转移的影响因素。,方法,2,收集结直肠癌根治术后复发转移患者的相关资料,以出现复发转移为终点事件,用Kaplan-Meier法对结直肠癌根治术后患者进行生存分析,采用log-rank检验对临床因素[性别、年龄、术前血清癌胚抗原水平、手术方式、原发肿瘤位置、中医证型、化学疗法(以下简称“化疗”)完成情况、口服中药情况]及病理因素(大体形状类型、肿瘤直径、组织学类型、分化程度、脉管和神经侵犯、癌结节、吻合口瘘、淋巴结转移、淋巴转移率、浸润深度、TNM分期、所检淋巴结个数)进行单因素分析,采用Cox回归模型进行多因素分析。,结果,2,①共收集417例病例,结直肠癌根治术后复发转移的高峰时间为术后10~12个月,中位无复发生存时间(RFS)为15.3个月。②单因素分析结果显示,组织学类型、分化程度、浸润深度、淋巴结转移、TNM分期、淋巴转移率、脉管和神经侵犯、癌结节、吻合口瘘、中医证型、化疗完成情况、口服中药情况与结直肠癌根治术后RFS相关(,P,<,0.05)。③多因素Cox回归分析结果显示,淋巴结转移[,OR,=1.724,95%,CI,(1.353,2.206)]、脉管和神经侵犯[,OR,=1.661,95%,CI,(1.116,2.465)]、癌结节[,OR,=1.801,95%,CI,(1.083,2.983)]、不同中医证型[,OR,=1.624,95%,CI,(1.126,2.473)]、完成全周期化疗[,OR,=1.738,95%,CI,(1.163,2.341)]、口服中药[,OR,=1.791,95%,CI,(1.328,2.264)]是影响结直肠癌术后RFS的独立危险因素,湿热内蕴证患者复发转移的风险较高,口服中药、完成全周期化疗可以延长患者的RFS。,结论,2,结直肠癌根治术后复发转移受淋巴结转移、脉管和神经侵犯、癌结节、化疗完成情况、中医证型、口服中药等因素影响,及早进行中医辨证论治有利于延长结直肠癌根治术后患者的生存期。
Objective,2,To explore the influencing factors of recurrence and metastasis after radical resection of colorectal cancer.,Methods,2,Data were collected on patients with recurrence and metastasis after radical resection of colorectal cancer, with the presence of recurrence and metastasis as the endpoint event. The Kaplan-Meier method was used to analyze the survival of patients after radical resection of colorectal cancer. The log-rank test was used perform univariate analysis on clinical factors (gender, age, preoperative serum carcinoembryonic antigen level, surgical method, primary tumor location, traditional Chinese medicine syndrome, completion of chemotherapy, and oral administration of traditional Chinese medicine) and pathological factors (overall shape type, tumor diameter, histological type, degree of differentiation, vascular and neural invasion, cancer nodules, anastomotic fistula, lymph node metastasis, lymphatic metastasis rate, infiltration depth, TNM staging, and number of lymph nodes detected). Cox regression model was used for multivariate analysis.,Results,2,①A total of 417 cases were collected, and the peak time for recurrence and metastasis after radical resection of colorectal cancer was 10~12 months after surgery, with a median relapse-free survival time (RFS) of 15.3 months. ②The results of univariate analysis showed that histological type, degree of differentiation, depth of infiltration, lymph node metastasis, TNM staging, lymph node metastasis rate, vascular and neural invasion, cancer nodules, anastomotic fistula, traditional Chinese medicine syndromes, completion of chemotherapy, and oral administration of traditional Chinese medicine were correlated with postoperative RFS of colorectal cancer (,P,<,0.05). ③The results of multivariate Cox regression analysis showed that lymph node metastasis [,OR,=1.724, 95%, CI, (1.353, 2.206)], vascular and neural invasion [,OR,=1.661, 95% ,CI, (1.116, 2.465)], cancer nodules [,OR,=1.801, 95%, CI, (1.083, 2.983)], different traditional Chinese medicine syndromes [,OR,=1.624, 95%, CI, (1.126, 2.473)], completion of full cycle chemotherapy [,OR,=1.738, 95%, CI, (1.163, 2.341)] and oral administration of traditional Chinese medicine [,OR,=1.791, 95%, CI, (1.328, 2.264)] were independent risk factors affecting RFS after colorectal cancer surgery. Patients with internal damp-heat accumulation syndrome had a higher risk of recurrence and metastasis. Oral administration of traditional Chinese medicine and completion of full cycle chemotherapy could prolong the RFS of patients.,Conclusions,2,The recurrence and metastasis of colorectal cancer after radical surgery are influenced by factors such as lymph node metastasis, vascular and neural invasion, cancer nodules, completion of chemotherapy, traditional Chinese medicine syndromes, and oral administration of traditional Chinese medicine. Early traditional Chinese medicine syndrome differentiation-based treatment is beneficial to prolong the survival of patients after radical resection of colorectal cancer.
大肠癌术后复发肿瘤转移中医证型中医药疗法生存时间
colorectal cancerpostoperative recurrencetumor metastasistraditional Chinese medicine syndrometraditional Chinese medicine therapysurvival time
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? [J]. Cancer Commun (Lond), 2019, 39(1): 22.
马爱娟,周脉耕,曾新颖,等. 1990年与2016年北京市恶性肿瘤疾病负担及其变化趋势[J]. 中华肿瘤杂志,2021, 43(3): 351-356.
鲍萍萍,吴春晓. 上海市癌症流行现况和防治实践[J]. 上海预防医学,2020, 32(11): 955-962.
VAN DER STOK E P, SPAANDER M C W, GRÜNHAGEN D J, et al. Surveillance after curative treatment for colorectal cancer[J]. Nat Rev Clin Oncol, 2017, 14(5): 297-315.
陈宁波,曾杰. 结直肠癌术后复发模式的临床研究及再手术治疗的预后分析[J]. 中华临床医师杂志(电子版),2016, 10(2): 198-202.
NOZAWA H, SONODA H, ISHII H, et al. Postoperative chemotherapy is associated with prognosis of stage Ⅳ colorectal cancer treated with preoperative chemotherapy/chemoradiotherapy and curative resection[J]. Int J Colorectal Dis, 2020, 35(1): 177-180.
秦文钰. 中医药干预下改善Ⅱ、Ⅲ期结直肠癌术后预后的定量与定性研究[D]. 北京:中国中医科学院,2020.
司富春,岳静宇. 近30年大肠癌中医证型和用药规律分析[J]. 中华中医药杂志,2012, 27(7): 1929-1931.
刘晓晨. 结直肠癌术后患者中医证候学规律初探[D]. 北京:北京中医药大学,2017.
杨利梅,张影茹,程悦蕾,等.靶向表皮生长因子受体治疗结直肠癌的耐药机制及中药研究进展[J]. 上海中医药杂志,2022, 56(2): 81-86.
中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)[J]. 中国实用外科杂志,2018, 38(10): 1089-1103.
国家药品监督管理局. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002: 12.
陈家旭. 中医诊断学(第二版)[M]. 北京:人民卫生出版社,2012: 5.
GUPTA N, KUPFER S S, DAVIS A M. Colorectal cancer screening[J]. JAMA, 2019, 321(20): 2022-2023.
BRENNER H, KLOOR M, POX C P. Colorectal cancer[J]. Lancet, 2014, 383(9927): 1490-1502.
VAN ROOIJEN S, CARLI F, DALTON S, et al. Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation[J]. BMC Cancer, 2019, 19(1): 98.
ANDREONI B, CHIAPPA A, BERTANI E, et al. Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients[J]. World J Surg Oncol, 2007, 5: 73.
陈月. 中晚期结直肠癌化疗及靶向治疗后副反应与中医证候的相关性研究[D]. 广州:广州中医药大学,2020.
KIRSTEIN M M, LANGE A, PRENZLER A, et al. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data[J]. Oncologist, 2014, 19(11): 1156-1168.
AHMED S, JOHNSON K, AHMED O, et al. Advances in the management of colorectal cancer: from biology to treatment[J]. Int J Colorectal Dis, 2014, 29(9): 1031-1042.
PALTA M, CZITO B G, WILLETT C G. Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue[J]. Nat Rev Clin Oncol, 2014, 11(4): 182-184.
杜薇,张宁苏,张惠子. 右半结肠癌术后中医证型与相关因素分析[J]. 实用中医内科杂志,2021, 35(5): 23-26.
GANESH K, MASSAGUÉ J. Targeting metastatic cancer[J]. Nat Med, 2021, 27(1): 34-44.
周冰川. 结直肠癌根治术后复发病例的回顾性分析[D]. 南宁:广西医科大学,2017.
张宇. 淋巴结转移度对Ⅲ期结直肠癌患者术后复发或转移影响的研究[J]. 中国预防医学杂志,2020, 21(4): 477-480.
潘丽,孙国平. 结直肠癌根治术后复发危险因素分层分析[J]. 中华肿瘤防治杂志,2018, 25(4): 270-274.
LEE J H, LEE J L, PARK I J, et al. Identification of recurrence-predictive indicators in stage Ⅰcolorectal cancer[J]. World J Surg, 2017, 41(4): 1126-1133.
ANDRÉ T, BONI C, MOUNEDJI-BOUDIAF L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med, 2004, 350(23): 2343-2351.
MORRIS M, PLATELL C, FRITSCHI L, et al. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage Ⅲ colon cancer patients[J]. Br J Cancer, 2007, 96(5): 701-707.
朱慧娟. 影响大肠癌肝转移的多因素回归分析[D]. 武汉:湖北中医药大学,2017.
陆晓,符炜,陆屸,等. 结直肠癌根治术后FOLFOX方案辅助化疗的临床疗效[J]. 江苏医药,2015, 41(15): 1804-1806.
靳永杰,周利红,刘宣,等. 从肾论治肿瘤[J]. 中国医药科学,2015, 5(9): 32-36.
李和根. 刘嘉湘辨治大肠癌经验[J]. 上海中医药杂志,2011, 45(8): 6-7.
张蕾. 大肠癌术后肝转移相关因素分析及中医证型特点研究[D]. 济南:山东中医药大学,2015.
韦宜宾. 334例大肠癌中医证候及其相关因素的回顾性研究[D]. 南宁:广西中医药大学,2016.
侯风刚,石齐,刘宣,等. 辨证、辨病治疗在中药预防结直肠癌术后复发转移中的作用[J]. 中华中医药杂志,2016, 31(6): 2154-2160.
范越,厉天瑜,张雯,等. 健脾解毒方防治大肠癌术后化疗相关周围神经病变的临床研究[J]. 上海中医药杂志,2018, 52(10): 49-53.
陶丽,朱莹杰,顾缨,等. 基于生存分析的胃肠安方辨证治疗对不可切除性结直肠癌肝转移预后影响的双向队列研究[J]. 上海中医药杂志,2017, 51(1): 42-49.
XU Y, MAO J J, SUN L, et al. Association between use of traditional Chinese medicine herbal therapy and survival outcomes in patients with stage Ⅱ and Ⅲ colorectal cancer: a multicenter prospective cohort study[J]. J Natl Cancer Inst Monogr, 2017, 2017(52): lgx015.
梁彐彐,李崇慧,张静,等. 扶正安中汤联合XELOX方案对结直肠癌术后辅助治疗的回顾性分析[J]. 中医药临床杂志,2019, 31(7): 1361-1364.
JIA R, LIU N, CAI G, et al. Effect of PRM1201 combined with adjuvant chemotherapy on preventing recurrence and metastasis of stage Ⅲ colon cancer: a randomized, double-blind, placebo-controlled clinical trial[J]. Front Oncol, 2021, 11: 618793.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构